title: Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma.
abstract: Two groups of children with acute lymphoblastic leukemia or non-Hodgkin lymphoma, treated with anthracyclines (ANT), were studied: group I, consisting of 10 patients, with coenzyme Q10 (CoQ) therapy; group II, consisting of 10 patients without CoQ therapy. The ANT cumulative dose was 240 +/- 20.0 mg/m2 in group I and 252.0 +/- 20.1 mg/m2 in group II. Echocardiographic study was performed at the beginning, at the cumulative dose of 180 mg/m2 and at the end of therapy with ANT. Percentage left ventricular fractional shortening (%LVFS) decreased from baseline (40.36 +/- 4.6) to end value (35.82 +/- 5.02) (P < 0.05) in group I; %LVFS decreased from baseline (39.89 +/- 4.37) to end value (33.43 +/- 3.46) (P < 0.002) in group II. Interventricular septum wall thickening decreased only in group II from baseline (46.10 +/- 10.1) to end therapy (27.00 +/- 18.54) (P < 0.01). Septum wall motion abnormalities were detected only in 2 patients of group II. These data demonstrate a protective effect of CoQ on cardiac function during therapy with ANT.
authors.affiliation: Medical-Surgery Institute of Cardiology, 2nd University of Naples, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Iarussi
authors.forename: U
authors.initials: U
authors.lastname: Auricchio
authors.forename: A
authors.initials: A
authors.lastname: Agretto
authors.forename: A
authors.initials: A
authors.lastname: Murano
authors.forename: M
authors.initials: M
authors.lastname: Giuliano
authors.forename: F
authors.initials: F
authors.lastname: Casale
authors.forename: P
authors.initials: P
authors.lastname: Indolfi
authors.forename: A
authors.initials: A
authors.lastname: Iacono
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D009202:Cardiomyopathies / Q000139:chemically induced / Q000517:prevention & control*; D002648:Child; D003067:Coenzymes; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D004452:Echocardiography; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors; D016896:Treatment Outcome; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D016277:Ventricular Function, Left
chemical_list: D003067:Coenzymes; D014451:Ubiquinone; C024989:coenzyme Q10; D003630:Daunorubicin